← All trials
NCT04720742
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2022
- First posted
- Jan 22, 2021
- Last posted
- Apr 20, 2021
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- IrsiCaixaLead sponsor
- Utrecht UniversityOverall official - principal investigator
- University of GranadaOverall official - principal investigator
- Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, MilanoOverall official - principal investigator
- Hospital General Universitario Gregorio MarañonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.